Showing results (151-160 of 686) with videos related to
Sort By:
Pageof 69
Current Pharmaceutical Design|January 3, 2013
Microalbuminuria: a neglected cardiovascular risk factor in non-diabetic individuals?Eirini Lioudaki, Matilda Florentin, Emmanuel S Ganotakis, et al.Current Vascular Pharmacology|May 1, 2013
Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overviewNiki Katsiki, Vasilios G Athyros, Asterios Karagiannis, et al.Current Pharmaceutical Design|February 22, 2008
Apolipoprotein E knockout modelsGenovefa Kolovou, Katherine Anagnostopoulou, Dimitri P Mikhailidis, et al.Current Vascular Pharmacology|November 2, 2012
Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertensionNiki Katsiki, Vasilios G Athyros, Dimitri P Mikhailidis, et al.Expert Opinion on Investigational Drugs|January 22, 2015
Fibroblast growth factor 19-targeted therapies for the treatment of metabolic diseaseJacek Rysz, Anna Gluba-Brzózka, Dimitri P Mikhailidis, et al.Expert Opinion on Pharmacotherapy|June 4, 2015
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 20, 2023
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical OverviewOzge Telci Caklili, Mustafa Cesur, Dimitri P Mikhailidis, et al.European Journal of Preventive Cardiology|August 14, 2021
Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overviewIoannis Parthymos, Michael S Kostapanos, Dimitri P Mikhailidis, et al.The Open Cardiovascular Medicine Journal|June 11, 2011
Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentVasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, et al.Current Medical Research and Opinion|February 1, 2011
Ezetimibe and low density lipoprotein subfractions: an ongoing debateNiki Katsiki, Vasilis G Athyros, Asterios Karagiannis, et al.Pageof 69